Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2009

View Archived Issues

Final data reported from phase Ib trial of atacicept in pretreated CLL patients

Romiplostim safe and effective in phase I/II study in pediatric ITP patients

Preliminary phase I safety and efficacy of IMGN-901 seen in pretreated MM patients

Novel TGR5 receptor agonists identified by AstraZeneca for type 2 diabetes treatment

Chroma Therapeutics describes novel Plk-1 inhibitors for cancer therapy

BMS identifies novel nAChR agonists

Biovitrum advances novel long-acting factor VIII-based hemophilia A therapy

FDA approves newly revised prescribing information for Teva's Azilect

Warner Chilcott affirms agreement with sanofi-aventis

Clinical data on candesartan in diabetic retinopathy disclosed at ISOPT

Pilot trial data indicate beneficial effects of Copaxone in dry AMD

Vorinostat in combination with tamoxifen safe and effective in phase II breast cancer trial

Daiichi Sankyo presents novel antibacterial compounds

Columbia University identifies VMAT2 ligands for the treatment of diabetes

Sanofi Pasteur expands study of Clostridium difficile vaccine to the U.S.

Celgene reports topline clinical phase IIb data on apremilast in psoriasis

Once-weekly exenatide superior to Byetta in type 2 diabetes patients

Nippon Shinyaku launches Erizas in Japan for the treatment of allergic rhinitis

Adcirca tablets launched by Nippon Shinyaku for pulmonary arterial hypertension

NDA submitted by Nippon Shinyaku for azacitidine in myelodysplastic syndromes

Novartis submits MAA to EMEA for Joulferon for hepatitis C

Primary endpoints unmet in Gilead's phase III darusentan trial in resistant hypertension

Lytix Biopharma obtains approval in Norway and Sweden for phase I trial of LTX-315

AstraZeneca and University of Virginia to collaborate on CAD and PDA therapies

Evotec receives milestone payment from Ono under collaboration on protease inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...